Company intelligence / Profile preview

SCOLR Pharma

Bothell, Washington, USAprnewswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

SCOLR Pharma developed a proprietary controlled-release oral drug delivery platform used in both prescription and over-the-counter products. Its lead candidate was a 12-hour extended-release ibuprofen that completed Phase III trials. Several nutritional supplement formulations using the CDT platform were commercialized through partnerships with Perrigo. The company was acquired by Probi USA in October 2016 and is no longer independently active.

Therapeutic areas: GastroenterologyPulmonologyCardiovascularPsychiatryImmunologyEndocrinologyOtherWomen's HealthNeurology
Modalities: Small moleculeNutritional productDevice
Industry: Biotech

Drug pipeline

1 asset

CDT-raloxifene

Discontinued

Partnerships

Perrigo Company of South Carolina—manufacture/distribution of dietary supplements using CDT technology

Beyond the preview

Go deeper on SCOLR Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCOLR Pharma.

Explore the full profile